I continue to be extremely impressed with the marketing skills of this development stage company.... They are superior to what we experienced with MAKO !!!!!
Sentiment: Strong Buy
Go to MZOR Yahoo website, then Investor Relations... Click on IR Conferences & it will be the 1st one listed ...
Very informative presentation or better said Q &A session with extremely comprehensive responses by the CEO !!!!
Excellent CC... wish he had been the CEO of MAKO ... he clearly understands his market, the selling process, keys to success, the physician's perspective/needs/wants, pricing startegy, etc.
Felt that his comment about NOT giving away MZOR's robotic surgical system to teaching/major medical centers was extremely revealing & insightful !!!!!!
Just pray that the rest of the management team & new hires are cut from the same mold... I trust that he has surrounded himself with a pool of talent & will hire wisely... ;-)
Naked $hort $elling. Is way of life & the SEC has proven again & again that it could care less !!!!!
Even though Intuitive Surgical handedly revolutionized the robotic surgery market, the company is now entering a phase of declining growth and margins due to pricing pressures from hospitals, and as competition finally begins to enter the relatively new marketplace, more and more emphasis will be placed on pricing and functionality when hospitals are exploring the purchase of a surgical robot. This is where TransEnterix (OTCQB:TRXC) steps in.
TransEnterix is a North Carolina-based medical device company that's focused on advanced minimally invasive surgery and is on the cusp of obtaining FDA 510(k) clearance for the Surgibot, a robotic surgical platform that addresses a number of problems and concerns associated with the da Vinci System. Because the Surgibot is expected to receive clearance and begin commercialization in mid 2015, the likelihood of TransEnterix's surgical robot becoming the first viable alternative for hospitals contemplating the purchase of a robotic system is very strong. Here's why TransEnterix represents an under valued medical device company that is gearing up for an extended period of growth and should generate significant returns for patient investors.
Yes, spine & brain surgery are high risk with MZOR providing a very strategic patient quality care alternative that directly impacts on reduced exposure to malpractice lawsuits !!!!!
Dr Buechel was Mako's force in the Asian market having trained several surgeons there & at his flagship medical center here in Naples FL... I love MZOR's timely announcements & candor as to details of what is occurring !!!!
Thanks again for your efforts... I agree with Q4 impact & would expect a banner 2015 from excellent unit & procedure growth ... GLTA !!!!!
Thanks for posting Don... What is your opinion on the impact of the brain surgery application on 2014 unit sales & procedure growth?
Happy New Year to you... This got too rich for my conservative nature ... Will be back later ... GLTY also !!!
$25 is the trigger point to start my research for a new entry point... More liking buying closer to $20 !!!
IMO... I believe what they are saying is $ell for now & place it on your watch list ... that is what I have done !!!
That type of utilzation combined with patient/quality of care benefits/results will turn heads in the surgical & hospital administration comunities... i am eager to get feedback directly from the medical community !!!
Limited info to date... Hope to gain significant insight from surgeons the next few months ... From both those using & not using the MZOR robotic system ... Need to hear about their experiences including the pros & cons !!!!
Got into MAKO at a similar point... plan to approach this investment the same way including discussions with as many surgeons using the technology as possible ...